CancerACT WONDER²SNCT06560398
Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)
A study testing Continuing Medical Education Events (CME), Trial Connect Portal and Clinical Trial Newsletters in people with Cancer, run by H. Lee Moffitt Cancer Center and Research Institute at 1 site in United States.
Trial summary
The purpose of the study is to refine, finalize, implement, and evaluate a multi-level intervention aimed at increasing enrollment of Black and Hispanic patients to National Cancer Institute (NCI)-sponsored therapeutic clinic trials at Moffitt Cancer Center. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cancer
- What is being tested?
- Continuing Medical Education Events (CME), Trial Connect Portal and Clinical Trial Newsletters
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 7,649 participants
- Where
- 1 siteUnited States
- Study dates
- 18 Sep 2024to 16 Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Community residents: Community residents may engage with various intervention components deployed in the intervention priority zones.
- Community Physicians: may engage with various intervention components deployed in the intervention priority zones if they 1) practice medicine in one of the geographic priority zones.
- Cancer Center Physicians: may engage with various intervention components if they 1) practice medicine at Moffitt.
- Clinical Research Coordinators (CRC): may engage with various intervention components if they 1) work as a CRC at Moffitt and 2) coordinate/pre-screen patients for at least 1 therapeutic clinical trial at Moffitt.
- Cancer Center Patients: may engage with various intervention components if they have an address that maps to an intervention priority zone and 2) are newly registered patients or new existing patients (NEPs).
Who cannot join
- Community residents, Community Physicians, Cancer Center Physicians, Clinical Research Coordinators, and Moffitt patients who do not meet the inclusion criteria.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Lindsay Fuzzell, PhD contact
United States1 site, 1 recruiting
- Recruiting
Moffitt Cancer Center
Tampa, Florida, 33612
Rossybelle Amorrortu, MPH, 813-745-4007, Rossybelle.Amorrortu@moffitt.org
Lindsay Fuzzell, PhD, Linsday.Fuzzell@moffitt.org
About this study
The purpose of the study is to refine, finalize, implement, and evaluate a multi-level intervention aimed at increasing enrollment of Black and Hispanic patients to National Cancer Institute (NCI)-sponsored therapeutic clinic trials at Moffitt Cancer Center.
Read the detailed description
A stratified cluster randomized design will be used to assess the impact of the Advancing Clinical Trials: Working through Outreach, Navigation, and Digitally Enabled Referral and Recruitment Strategies (ACT WONDER²S) multi-level intervention on increasing referral and enrollment to NCI-sponsored therapeutic clinical trials among Black and Hispanic patients. Geospatial analytics were used to identify clusters of census tracts within the Moffitt catchment area ("priority zones") with high Black and Hispanic populations for intervention deployment. Priority zones were then matched on population characteristics and randomized to receive the intervention (n=7) or to serve as controls (n=7).
External target populations within the Catchment Area Priority Zone (CAPZ) include community residents and community physicians, while internal target populations within Moffitt Cancer Center (Moffitt) include physicians, clinical research coordinators (CRCs), and patients. The outreach and education intervention components will be facilitated by community health educators (CHEs) targeting community residents (Clinical Trial Education module and CHE support through the ACT WONDER²S Phone-line/Email), community physicians (Continuing Medical Education sessions including implicit bias training), patients at Moffitt (CHE support) and cancer center physicians/CRCs (an implicit bias training). Digitally enabled decision support tools will be developed and deployed to the CHE's (a data-empowered interactive map for outreach planning [Precision Engagement Tool]), community physicians (Clinical Trial Newsletters), patients at Moffitt (a clinical trial decision aid [CHOICES DA]), and cancer center physicians/CRCs (a recruitment dashboard to monitor clinical trial accrual rates, a clinical trial portfolio profiler, and a tool to assess the impact of clinical trial inclusion/exclusion criteria on eligibility across patient populations defined by age, race, and ethnicity [Eligibility Criteria Calculator]). In addition, an online portal (called the Trial Connect Portal) will be developed to connect community-based referring physicians to information about MCC trials and to facilitate their communication with cancer center physicians and CRCs. The primary outcome, enrollment to clinical trials, will be measured by comparing the percentage of Moffitt patients enrolled on NCI-supported treatment trials who are Black or Hispanic between intervention priority zones and the control priority zones. The secondary outcome, referral to Moffitt, will be measured by comparing the percentage of patients referred to Moffitt who are Black or Hispanic between the intervention priority zones and the control priority zones.
- Conditions
- Cancer
- Being tested
- Continuing Medical Education Events (CME), Trial Connect Portal, Clinical Trial Newsletters, Implicit Bias Training, Recruitment Dashboard
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Continuing Medical Education Events (CME)Behavioural
An engaging 1-hour informational session focusing on topic areas such as implicit bias and emerging evidence from recent cancer clinical trials with CME credit or American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) points available.
Trial Connect PortalBehavioural
A digital tool to help facilitate rapid referral of patients to clinical trial opportunities at Moffitt.
Clinical Trial NewslettersBehavioural
Electronic/paper newsletters to highlight open trials at Moffitt that will be distributed by email/mail.
Implicit Bias TrainingBehavioural
A one-hour educational module will cover information on implicit bias to support the recruitment of diverse patients.
Recruitment DashboardBehavioural
A dynamic dashboard depicting the number of patients recruited to clinical trials by gender, race, ethnicity, age, cancer type, residence in the catchment area, and other key clinical characteristics.
Portfolio ProfilerBehavioural
An interactive dashboard to allow cancer center physicians easily identify gaps in the current clinical trial portfolio that may be contributing to racial/ethnic disparities in trial enrollment.
Eligibility CalculatorBehavioural
A digital calculator that will allow for assessment of the potential impact of clinical trial eligibility criteria (e.g., comorbidities, age, lab values) that may disproportionately exclude patients who are Black and Hispanic prior to submission of clinical trial protocols to the Scientific Review Committee.
Clinical Trial Education Sessions (Community Residents Only)Behavioural
An engaging 1-hour educational session delivered by a community health educator that includes basic information about clinical trials, their importance, myths, need for diversity in the trials process, and resources for finding more information about clinical trials.
ACT WONDER²S Phone-line/Email (Community Residents and Moffitt Patients)Behavioural
A study team member will be available for questions via a dedicated phone-line and email for community residents and Moffitt patients with a return contact within 24-hours.
New Patient Information (Moffitt Patients Only)Behavioural
Including CHOICES DA, a web-based tool to improve multiple aspects of decision-making related to participation in cancer clinical trials.
No InterventionOther
Control group with no intervention.
| Study group | Role | What they receive |
|---|---|---|
| Catchment Area Priority Zone (CAPZ) Intervention - Community Residents and Moffitt Patients | Experimental | Study interventions will be deployed in geographically defined intervention priority zones including Clinical Trial Education sessions and the ACT WONDER²S Phone-line/Email. Community residents in these zones may be exposed to these interventions.
Residents who are also new patients to Moffitt may be exposed to the CHOICES DA website once they are registered at Moffitt. Receives: Behavioral: Clinical Trial Education Sessions (Community Residents Only); Behavioral: ACT WONDER²S Phone-line/Email (Community Residents and Moffitt Patients); Behavioral: New Patient Information (Moffitt Patients Only) |
| Catchment Area Priority Zone (CAPZ) Control - Community Residents and Moffitt Patients | Active comparator | Study interventions will not be deployed in the control priority zones. Community residents in these zones are unlikely to be exposed to any of the study interventions. Receives: Other: No Intervention |
| Catchment Area Priority Zone (CAPZ) Intervention - Community Physicians | Experimental | Study interventions will be deployed in geographically defined intervention priority zones including Continuing Medical Education events, the Trial Connect Portal, and Clinical Trial Newsletters. Community physicians in these zones may be exposed to these interventions. Receives: Behavioral: Continuing Medical Education Events (CME); Behavioral: Trial Connect Portal; Behavioral: Clinical Trial Newsletters |
| Catchment Area Priority Zone (CAPZ) Control- Community Physicians | Active comparator | Study interventions will not be deployed in the control priority zones. Community physicians in these zones are unlikely to be exposed to any of the study interventions. Receives: Other: No Intervention |
| Cancer Center Clinical Research Coordinators (CRCs) | Experimental | CRCs that work on therapeutic clinical trials at Moffitt will have access to the implicit bias educational module and digital tools to monitor and enhance minority recruitment, including the Trial Connect Portal and Recruitment Dashboard. Receives: Behavioral: Trial Connect Portal; Behavioral: Implicit Bias Training; Behavioral: Recruitment Dashboard |
| Cancer Center Physicians | Experimental | Physicians at Moffitt will have access to the implicit bias educational module and to digital tools to monitor and enhance minority recruitment, including the Trial Connect Portal, Recruitment Dashboard, Portfolio Profiler, and the Eligibility Criteria Calculator. Receives: Behavioral: Trial Connect Portal; Behavioral: Implicit Bias Training; Behavioral: Recruitment Dashboard; Behavioral: Portfolio Profiler; Behavioral: Eligibility Calculator |
What is being measured
The primary outcome is the main question the study is designed to answer.
Enrollment of Black and Hispanic Patients to NCI-sponsored cancer treatment clinical trials
Intervention impact on enrollment rates will be measured by comparing the percentage of Moffitt patients enrolled on NCI-supported treatment trials who are Black or Hispanic between intervention priority zones and the control priority zones.
Measured: 2 years
Secondary outcomes (5)
Referral of Black and Hispanic Patients to Moffitt Cancer Center
Intervention impact on referral rates will be measured by comparing the percentage of patients referred to Moffitt who are Black or Hispanic between the intervention priority zones and the control priority zones.
Measured: 2 Years
Community residents in the intervention CAPZ
The number of community residents that attend a CT educational session.
Measured: 2 years
Community physicians in the intervention CAPZ
The number of physicians that attend a CME event.
Measured: 2 years
Cancer Center CRC
The number of CRCs that used at least one of the CT digital tools.
Measured: 2 years
Cancer Center Physician
The number of MCC physicians that used at least one of the CT digital tools.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Aug 2024
- Study start18 Sep 2024
- Primary completion16 Sep 2026 (estimated)
- Study completion16 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by H. Lee Moffitt Cancer Center and Research InstituteThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 7,649 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Susan Vadaparampil, PhD, Principal investigator, Moffitt Cancer CenterDana Rollison, PhD, Principal investigator, Moffitt Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06560398
- Sponsor's protocol ID
- MCC-22140
- Other IDs
- U01CA274971-01
- Acronym
- ACT WONDER²S
- Status last verified
- Sep 2026
- First submitted
- 15 Aug 2024
- Last updated
- 3 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)
- ClinicalTrials.gov ID
- NCT06560398
- Acronym / sponsor ID
- ACT WONDER²S / MCC-22140
- Conditions
- Cancer
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 7,649 participants (estimated)
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research InstituteUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 18 Sep 2024 (actual)
- Primary completion
- 16 Sep 2026 (estimated)
- Study completion
- 16 Sep 2026 (estimated)
- First posted
- 19 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to refine, finalize, implement, and evaluate a multi-level intervention aimed at increasing enrollment of Black and Hispanic patients to National Cancer Institute (NCI)-sponsored therapeutic clinic trials at Moffitt Cancer Center.
Detailed description
A stratified cluster randomized design will be used to assess the impact of the Advancing Clinical Trials: Working through Outreach, Navigation, and Digitally Enabled Referral and Recruitment Strategies (ACT WONDER²S) multi-level intervention on increasing referral and enrollment to NCI-sponsored therapeutic clinical trials among Black and Hispanic patients. Geospatial analytics were used to identify clusters of census tracts within the Moffitt catchment area ("priority zones") with high Black and Hispanic populations for intervention deployment. Priority zones were then matched on population characteristics and randomized to receive the intervention (n=7) or to serve as controls (n=7).
External target populations within the Catchment Area Priority Zone (CAPZ) include community residents and community physicians, while internal target populations within Moffitt Cancer Center (Moffitt) include physicians, clinical research coordinators (CRCs), and patients. The outreach and education intervention components will be facilitated by community health educators (CHEs) targeting community residents (Clinical Trial Education module and CHE support through the ACT WONDER²S Phone-line/Email), community physicians (Continuing Medical Education sessions including implicit bias training), patients at Moffitt (CHE support) and cancer center physicians/CRCs (an implicit bias training). Digitally enabled decision support tools will be developed and deployed to the CHE's (a data-empowered interactive map for outreach planning [Precision Engagement Tool]), community physicians (Clinical Trial Newsletters), patients at Moffitt (a clinical trial decision aid [CHOICES DA]), and cancer center physicians/CRCs (a recruitment dashboard to monitor clinical trial accrual rates, a clinical trial portfolio profiler, and a tool to assess the impact of clinical trial inclusion/exclusion criteria on eligibility across patient populations defined by age, race, and ethnicity [Eligibility Criteria Calculator]). In addition, an online portal (called the Trial Connect Portal) will be developed to connect community-based referring physicians to information about MCC trials and to facilitate their communication with cancer center physicians and CRCs. The primary outcome, enrollment to clinical trials, will be measured by comparing the percentage of Moffitt patients enrolled on NCI-supported treatment trials who are Black or Hispanic between intervention priority zones and the control priority zones. The secondary outcome, referral to Moffitt, will be measured by comparing the percentage of patients referred to Moffitt who are Black or Hispanic between the intervention priority zones and the control priority zones.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Catchment Area Priority Zone (CAPZ) Intervention - Community Residents and Moffitt Patients | Experimental | Behavioral: Clinical Trial Education Sessions (Community Residents Only), Behavioral: ACT WONDER²S Phone-line/Email (Community Residents and Moffitt Patients), Behavioral: New Patient Information (Moffitt Patients Only)Study interventions will be deployed in geographically defined intervention priority zones including Clinical Trial Education sessions and the ACT WONDER²S Phone-line/Email. Community residents in these zones may be exposed to these interventions. Residents who are also new patients to Moffitt may be exposed to the CHOICES DA website once they are registered at Moffitt. |
| Catchment Area Priority Zone (CAPZ) Control - Community Residents and Moffitt Patients | Active comparator | Other: No InterventionStudy interventions will not be deployed in the control priority zones. Community residents in these zones are unlikely to be exposed to any of the study interventions. |
| Catchment Area Priority Zone (CAPZ) Intervention - Community Physicians | Experimental | Behavioral: Continuing Medical Education Events (CME), Behavioral: Trial Connect Portal, Behavioral: Clinical Trial NewslettersStudy interventions will be deployed in geographically defined intervention priority zones including Continuing Medical Education events, the Trial Connect Portal, and Clinical Trial Newsletters. Community physicians in these zones may be exposed to these interventions. |
| Catchment Area Priority Zone (CAPZ) Control- Community Physicians | Active comparator | Other: No InterventionStudy interventions will not be deployed in the control priority zones. Community physicians in these zones are unlikely to be exposed to any of the study interventions. |
| Cancer Center Clinical Research Coordinators (CRCs) | Experimental | Behavioral: Trial Connect Portal, Behavioral: Implicit Bias Training, Behavioral: Recruitment DashboardCRCs that work on therapeutic clinical trials at Moffitt will have access to the implicit bias educational module and digital tools to monitor and enhance minority recruitment, including the Trial Connect Portal and Recruitment Dashboard. |
| Cancer Center Physicians | Experimental | Behavioral: Trial Connect Portal, Behavioral: Implicit Bias Training, Behavioral: Recruitment Dashboard, Behavioral: Portfolio Profiler, Behavioral: Eligibility CalculatorPhysicians at Moffitt will have access to the implicit bias educational module and to digital tools to monitor and enhance minority recruitment, including the Trial Connect Portal, Recruitment Dashboard, Portfolio Profiler, and the Eligibility Criteria Calculator. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Community residents: Community residents may engage with various intervention components deployed in the intervention priority zones.
- Community Physicians: may engage with various intervention components deployed in the intervention priority zones if they 1) practice medicine in one of the geographic priority zones.
- Cancer Center Physicians: may engage with various intervention components if they 1) practice medicine at Moffitt.
- Clinical Research Coordinators (CRC): may engage with various intervention components if they 1) work as a CRC at Moffitt and 2) coordinate/pre-screen patients for at least 1 therapeutic clinical trial at Moffitt.
- Cancer Center Patients: may engage with various intervention components if they have an address that maps to an intervention priority zone and 2) are newly registered patients or new existing patients (NEPs).
Key exclusion criteria (1 listed)
- Community residents, Community Physicians, Cancer Center Physicians, Clinical Research Coordinators, and Moffitt patients who do not meet the inclusion criteria.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Continuing Medical Education Events (CME)An engaging 1-hour informational session focusing on topic areas such as implicit bias and emerging evidence from recent cancer clinical trials with CME credit or American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) points available. | Behavioural | Catchment Area Priority Zone (CAPZ) Intervention - Community Physicians |
| Trial Connect PortalA digital tool to help facilitate rapid referral of patients to clinical trial opportunities at Moffitt. | Behavioural | Cancer Center Clinical Research Coordinators (CRCs), Cancer Center Physicians, Catchment Area Priority Zone (CAPZ) Intervention - Community Physicians |
| Clinical Trial NewslettersElectronic/paper newsletters to highlight open trials at Moffitt that will be distributed by email/mail. | Behavioural | Catchment Area Priority Zone (CAPZ) Intervention - Community Physicians |
| Implicit Bias TrainingA one-hour educational module will cover information on implicit bias to support the recruitment of diverse patients. | Behavioural | Cancer Center Clinical Research Coordinators (CRCs), Cancer Center Physicians |
| Recruitment DashboardA dynamic dashboard depicting the number of patients recruited to clinical trials by gender, race, ethnicity, age, cancer type, residence in the catchment area, and other key clinical characteristics. | Behavioural | Cancer Center Clinical Research Coordinators (CRCs), Cancer Center Physicians |
| Portfolio ProfilerAn interactive dashboard to allow cancer center physicians easily identify gaps in the current clinical trial portfolio that may be contributing to racial/ethnic disparities in trial enrollment. | Behavioural | Cancer Center Physicians |
| Eligibility CalculatorA digital calculator that will allow for assessment of the potential impact of clinical trial eligibility criteria (e.g., comorbidities, age, lab values) that may disproportionately exclude patients who are Black and Hispanic prior to submission of clinical trial protocols to the Scientific Review Committee. | Behavioural | Cancer Center Physicians |
| Clinical Trial Education Sessions (Community Residents Only)An engaging 1-hour educational session delivered by a community health educator that includes basic information about clinical trials, their importance, myths, need for diversity in the trials process, and resources for finding more information about clinical trials. | Behavioural | Catchment Area Priority Zone (CAPZ) Intervention - Community Residents and Moffitt Patients |
| ACT WONDER²S Phone-line/Email (Community Residents and Moffitt Patients)A study team member will be available for questions via a dedicated phone-line and email for community residents and Moffitt patients with a return contact within 24-hours. | Behavioural | Catchment Area Priority Zone (CAPZ) Intervention - Community Residents and Moffitt Patients |
| New Patient Information (Moffitt Patients Only)Including CHOICES DA, a web-based tool to improve multiple aspects of decision-making related to participation in cancer clinical trials. | Behavioural | Catchment Area Priority Zone (CAPZ) Intervention - Community Residents and Moffitt Patients |
| No InterventionControl group with no intervention. | Other | Catchment Area Priority Zone (CAPZ) Control - Community Residents and Moffitt Patients, Catchment Area Priority Zone (CAPZ) Control- Community Physicians |
Primary outcome
Enrollment of Black and Hispanic Patients to NCI-sponsored cancer treatment clinical trials
Time frame: 2 years
Intervention impact on enrollment rates will be measured by comparing the percentage of Moffitt patients enrolled on NCI-supported treatment trials who are Black or Hispanic between intervention priority zones and the control priority zones.
5 secondary outcomes
Referral of Black and Hispanic Patients to Moffitt Cancer Center
Time frame: 2 Years
Community residents in the intervention CAPZ
Time frame: 2 years
Community physicians in the intervention CAPZ
Time frame: 2 years
Cancer Center CRC
Time frame: 2 years
Cancer Center Physician
Time frame: 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2026.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lindsay Fuzzell, PhD contact
Susan Vadaparampil, PhD principal investigator
Moffitt Cancer Center
Dana Rollison, PhD principal investigator
Moffitt Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Continuing Medical Education Events (CME), Trial Connect Portal and Clinical Trial Newsletters in people with Cancer, run by H. Lee Moffitt Cancer Center and Research Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rossybelle Amorrortu, MPH (813-745-4007, Rossybelle.Amorrortu@moffitt.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Enrollment of Black and Hispanic Patients to NCI-sponsored cancer treatment clinical trials (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.